How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer

BJU International

Volumn 101, Issue 8, 2008, Pages 944-947

  Van Vulpen, Marco ^a   Van Der Heide, Uulke A ^a   Van Moorselaar, Jeroen R J A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RADIATION DOSE; SHORT SURVEY; UROLOGY;

FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 41049084276     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07346.x     Document Type: Short Survey

References (22)

1. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997 349 : 906 10
2. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs Radiation Therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004 292 : 821 7
3. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 360 : 103 6
4. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 61 : 1285 90
5. Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in radiotherapy for localized prostate cancer. results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006 24 : 1990 6
6. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002 54 : 677 85
7. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography? BJU Int 2006 98 : 982 5
8. Teh BS, Bastasch MD, Mai WY, Butler EB, Wheeler TM. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J 2003 9 : 454 60
9. Dehnad H, Nederveen AJ, van Der Heide UA, Van Moorselaar RJ, Hofman P, Lagendijk JJ. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol 2003 67 : 295 302
10. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI. a multi-observer study. Int J Radiat Oncol Biol Phys 1999 43 : 57 66
11. Nederveen AJ, Dehnad H, van Der Heide UA, Van Moorselaar RJ, Hofman P, Lagendijk JJ. Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol 2003 68 : 81 8
12. Van der Heide UA, Dehnad H, Hofman P, Kotte ANTJ, Lagendijk JJW, Van Vulpen M. Analysis of fiducial marker based position verification in the intensity-modulated radiotherapy of patients with prostate cancer. Radioth Onc 2007 82 : 38 45
13. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000 89 : 1800 9
14. De Crevoisier R, Tucker SL, Dong L et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005 62 : 965 73
15. Milosevic M, Voruganti S, Blend R et al. Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography. Radiother Oncol 1998 47 : 277 84
16. Futterer JJ, Engelbrecht MR, Huisman HJ et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005 237 : 541 9
17. Villeirs GML, Verstraete K, De Neve WJ, De Meerleer GO. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 2005 76 : 99 106
18. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005 294 : 1233 9
19. Ling CC, Humm J, Larson S et al. Towards multidimensional radiotherapy (MD-CRT). biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000 47 : 551 60
20. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003 57 : 391 401
21. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes FollowIng treatment for ClInically localized prostate cancer In a population based cohort. J Urol 2007 177 : 932 6
22. Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004 58 : 25 33